Ontology highlight
ABSTRACT:
SUBMITTER: Assouline SE
PROVIDER: S-EPMC4972610 | biostudies-literature | 2016 Jul
REPOSITORIES: biostudies-literature
Assouline Sarit E SE Nielsen Torsten Holm TH Yu Stephen S Alcaide Miguel M Chong Lauren L MacDonald David D Tosikyan Axel A Kukreti Vishal V Kezouh Abbas A Petrogiannis-Haliotis Tina T Albuquerque Marco M Fornika Daniel D Alamouti Sepideh S Froment Remi R Greenwood Celia M T CM Oros Kathleen Klein KK Camglioglu Errol E Sharma Ayushi A Christodoulopoulos Rosa R Rousseau Caroline C Johnson Nathalie N Crump Michael M Morin Ryan D RD Mann Koren K KK
Blood 20160510 2
The majority of diffuse large B-cell lymphoma (DLBCL) tumors contain mutations in histone-modifying enzymes (HMEs), indicating a potential therapeutic benefit of histone deacetylase inhibitors (HDIs), and preclinical data suggest that HDIs augment the effect of rituximab. In this randomized phase 2 study, we evaluated the response rate and toxicity of panobinostat, a pan-HDI administered 30 mg orally 3 times weekly, with or without rituximab, in 40 patients with relapsed or refractory de novo (n ...[more]